Pharmacoproteomic Analysis of Prechemotherapy and Postchemotherapy Plasma Samples from Patients Receiving Neoadjuvant or Adjuvant Chemotherapy for Breast Carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Cyclophosphamide
  • Doxorubicin
  • Fluorouracil
  • Neoadjuvant Therapy
  • Proteomics

abstract

  • A single chemotherapy-inducible SELDI-MS peak and five other peaks that distinguished plasma obtained from patients with breast carcinoma from plasma obtained from normal, healthy women were identified. The (as yet unsequenced) proteins represented by these peaks are candidate markers of micrometastatic disease after surgery.

publication date

  • May 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.20203

PubMed ID

  • 15112261

Additional Document Info

start page

  • 1814

end page

  • 22

volume

  • 100

number

  • 9